Intravenous or intramuscular injections of iron dextran are indicated for treatment of patients with documented iron deficiency in whom oral administration is unsatisfactory or impossible.

Oral iron should be discontinued prior to administration of INFeD.

Dosage

Iron Deficiency Anemia: Periodic hematologic determination (hemoglobin and hematocrit) is a simple and accurate technique for monitoring hematological response and should be used as a guide in therapy. It should be recognized that iron storage may lag behind the appearance of normal blood morphology. Serum iron, total iron binding capacity (TIBC) and percent saturation of transferrin are other important tests for detecting and monitoring the iron deficient state. After administration of iron dextran complex, evidence of a therapeutic response can be seen in a few days as an increase in the reticulocyte count.

Although serum ferritin is usually a good guide to body iron stores, the correlation of body iron stores and serum ferritin may not be valid in patients on chronic renal dialysis who are also receiving iron dextran complex.

Although there are significant variations in body build and

INFeD® (Iron Dextran Injection, USP) containing 50 mg of elemental iron per mL, is available in 2 mL single dose amber vials (for intramuscular or intravenous use) in cartons of 10 (NDC 52544-931-02).

Store at controlled room temperature 15°-30° C (59°-86° F).

CAUTION: Federal law prohibits dispensing without prescription.

REFERENCES

1. Hatton RC, Portales IT, Finlay A, Ross EA, Removal of Iron Dextran by Himodialysis: An In Vitro Study. Am d Kid Dis. 1995; 26( 2), 327-330.

2. Manuel MA, Stewart WK, St. Clair Neill GD, Hutchinson F. Loss of Iron- Dextran through Cuprophane Membrane of a Disposable Coil Dialyser. Nephron. 1972; 9: 94-98.

Literature revised: February 2001

Product No.: 1001-02


Watson Pharma, Inc.
a subsidiary of Watson Pharmaceuticals, Inc.
Morristown, NJ 07962 USA

Bookmark this page: